New “Semisynthetic” Anti-Malarial Drug is Unneeded and Sets Dangerous Precedent While Threatening Farmer Livelihoods
By Press Release,
SynBioWatch
| 04. 15. 2013
SynBioWatch Press Release:
For Immediate Release
April 15, 2013
Contact: Lisa Archer, Gopal Dayaneni, or Tina Stevens, , (510) 982-1285, info@SynBioWatch.org
Pharmaceutical giant Sanofi Aventis and Amyris Biotech founder Jay Keasling have announced that they intend to replace the entire world supply of the World Health Organization’s preferred anti-malarial treatment derived from botanical artemisinin with a semisynthetic product which employs synthetic biology, a controversial, unregulated biotechnology.
Speaking at a conference in Cambridge, UK, Keasling said, “Moves are afoot to replace the entire world supply” of artemisinin, which is currently produced by thousands of farmers in Kenya, Tanzania, Madagascar, Mozambique, India, Vietnam and China who cultivate sweet wormwood, the natural source of artemisinin. The statement was confirmed in a release by Sanofi outlining their plan to begin large-scale production.
Currently unregulated, synthetic biology is an extreme form of genetic engineering that involves replacing the genetic material of microbes with entirely artificial human designed gene sequences, resulting in new organisms that are then ‘put to work’ as microbial ‘factories.’
The news raised a host of red flags among civil society organizations concerned...
Related Articles
By Vuyile Madwantsi, Independent Online | 08.22.2025
Imagine this: a future where parents could choose their baby’s eye colour, height or even intelligence.
Sounds like science fiction, right? But it’s closer than you think.
Let’s start with a simple, human truth: most of us want healthy children...
The Center for Genetics and Society is delighted to recommend the current edition of GMWatch Review – Number 589. UK-based GMWatch, a long-standing ally, was founded in 1998 by Jonathan Matthews as an independent organization seeking to counter the enormous corporate political power and propaganda of the GMO industry and its supporters. Matthews and Claire Robinson are its directors and managing editors.
CGS works to ensure that social justice, equity, human rights, and democratic governance are front...
By Harry Hunter, PET BioNews | 08.11.2025
The Parliamentary Office of Science and Technology has announced plans to publish a POSTnote and called for submissions on surrogacy law in the UK and internationally.
The current UK surrogacy laws, largely based on legislation from the 1980s, have been...
By Cade Metz, The New York Times | 08.04.2025
Image by Mike MacKenzie / CC BY 2.0
In downtown Berkeley, an old hotel has become a temple to the pursuit of artificial intelligence and the future of humanity. Its name is Lighthaven.
Covering much of a city block, this...
